Literature DB >> 9564487

Difficult-to-treat trichomoniasis: results with paromomycin cream.

P Nyirjesy1, J D Sobel, M V Weitz, D J Leaman, S P Gelone.   

Abstract

Vaginal trichomoniasis poses a difficult therapeutic challenge when metronidazole is ineffective or contraindicated. We conducted a retrospective study of 6.25% paromomycin cream in the treatment of nine women referred with cases of vaginal trichomoniasis where metronidazole resistance or allergy was present. Results obtained immediately and 1 month after treatment were reviewed. The median age of the patients was 46 years; four women were nulliparous. The median symptom duration was 1 year. Five women were allergic to metronidazole. In four cases, resistance to high doses of metronidazole was demonstrated. Smears or cultures were positive immediately after treatment for three patients; a fourth relapsed 2 weeks later. Of these patients for whom treatment failed, one was cured with a 3-week course of paromomycin cream, and another was successfully treated with paromomycin cream and oral tinidazole. Three patients developed vaginal ulcerations that resolved spontaneously. Adverse effects may be a result of local formulation. Paromomycin cream was useful for treatment of cases of trichomonas infection where metronidazole resistance or allergy was encountered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564487     DOI: 10.1086/513951

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Managing Resistant Trichomonas Vaginitis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

2.  Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations.

Authors:  T Meri; T S Jokiranta; L Suhonen; S Meri
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Molecular characterization of Trichomonas tenax causing pulmonary infection.

Authors:  Hassan Mallat; Isabelle Podglajen; Véronique Lavarde; Jean-Luc Mainardi; Jérôme Frappier; Muriel Cornet
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 4.  Strategies for Prevention and Treatment of Trichomonas vaginalis Infections.

Authors:  Kawthar Bouchemal; Christian Bories; Philippe M Loiseau
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

5.  Antimicrobial Resistance in Vulvovaginitis.

Authors:  Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

6.  Anti-parasitic activity of nano Citrullus colocynthis and nano Capparis spinose against Trichomonas vaginalis in vitro.

Authors:  Musafer H Al-Ardi
Journal:  J Parasit Dis       Date:  2021-03-13

7.  Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 20.999

8.  Bond-based linear indices in QSAR: computational discovery of novel anti-trichomonal compounds.

Authors:  Yovani Marrero-Ponce; Alfredo Meneses-Marcel; Oscar M Rivera-Borroto; Ramón García-Domenech; Jesus Vicente De Julián-Ortiz; Alina Montero; José Antonio Escario; Alicia Gómez Barrio; David Montero Pereira; Juan José Nogal; Ricardo Grau; Francisco Torrens; Christian Vogel; Vicente J Arán
Journal:  J Comput Aided Mol Des       Date:  2008-05-16       Impact factor: 3.686

Review 9.  A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.

Authors:  Elissa Meites; Charlotte A Gaydos; Marcia M Hobbs; Patricia Kissinger; Paul Nyirjesy; Jane R Schwebke; W Evan Secor; Jack D Sobel; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

10.  Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).

Authors:  Viroj Wiwanitkit
Journal:  Ther Clin Risk Manag       Date:  2012-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.